GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Debt-to-Asset

NextGen Biomed (XTAE:NXGN) Debt-to-Asset : 0.00 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Debt-to-Asset?

NextGen Biomed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₪0.00 Mil. NextGen Biomed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₪0.00 Mil. NextGen Biomed's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was ₪12.82 Mil. NextGen Biomed's debt to asset for the quarter that ended in Jun. 2023 was 0.00.


NextGen Biomed Debt-to-Asset Historical Data

The historical data trend for NextGen Biomed's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Debt-to-Asset Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only - - - - -

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NextGen Biomed's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Debt-to-Asset falls into.



NextGen Biomed Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NextGen Biomed's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

NextGen Biomed's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextGen Biomed  (XTAE:NXGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


NextGen Biomed Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.